A technical deep dive for IP teams, portfolio managers, R&D leads, and institutional investors in biologics and biosimilar development. Why […]

A single drug can generate $10 billion in annual revenue. The same drug, one day after its last relevant patent

“The average branded drug loses roughly 80% of its revenue within 12 months of generic entry. What happens in the

Russia’s Drug Machine: Inside the Industry That Rewired Itself Overnight In 2024, the total value of the market reached 2.85

How patent cliffs, dual disease burdens, and a rising global middle class are redrawing the map of pharmaceutical competition —

The median pharmaceutical patent case where more than $25 million is at risk costs $4 million to litigate through trial

A technical deep dive for professionals who need more than a checklist. This is the architecture of a market-winning generic

For pharma IP teams, portfolio managers, R&D leads, and institutional investors tracking the $72B biosimilar market. 1. Executive Summary and

The U.S. healthcare system has already saved an estimated $23.6 billion from biosimilar use [1]. Yet for all that money